



May 30, 2025

Company name:	SanBio Co., Ltd. (Code: 4592 TSE Growth)
Name of representative:	Keita Mori, Representative Director and President
For inquiries, contact:	Yoshihiro Kakutani, Corporate Officer of Management Administration (Phone: 03-6264-3481)

**Keita Mori, Representative Director and President of SanBio, Appointed
Chairman of Samurai Biotech Association**

SanBio Co., Ltd. hereby provides on this matter as per the attached document.



May 30, 2025
SanBio Co., Ltd.

**Keita Mori, Representative Director and President of SanBio, Appointed
Chairman of Samurai Biotech Association**

SanBio Co., Ltd. (Head office: Tokyo, Representative Director and President: Keita Mori) announces that its Representative Director and President, Keita Mori, has been appointed Chairman of the Samurai Biotech Association.

The Samurai Biotech Association (the “Association”) serves as a bridge connecting the voices of member companies with society and public policy. Its core activities focus on public-private dialogue and policy advocacy in fields centered on biotechnology, including pharmaceuticals, medical devices, regenerative medicine products, and medical technologies.

Mr. Mori’s full message upon assuming the chairmanship is available on the Association’s official website:

<http://samurai-biotech.jp/>

<Excerpt from Mr. Mori’s message>

The Association has played a key role in bridging the voices of its member companies with society and public policy, with a focus on public-private dialogue and policy proposals in fields centered on biotechnology—including pharmaceuticals, medical devices, regenerative medicine products, and medical technologies. In particular, the entrepreneurial spirit and flexibility unique to startups serve as a driving force that transforms innovation into reality and paves the way for the future of Japan’s healthcare and industries.

Rather than simply nurturing the industry, we are committed to ensuring that the outcomes of innovation reach every patient in a tangible way. To deliver cutting-edge technologies and therapies to the front lines of healthcare as swiftly as possible, it is essential to reassess existing systems and policies and to foster an environment that reflects the needs of a changing era.

Amid growing uncertainty in society, we believe it is essential to reaffirm our sense of mission as an industry and to work toward the realization of truly valuable healthcare by strengthening collaboration both in Japan and abroad. Operating in the global market, we will also actively contribute to policy development and regulatory reform to ensure that innovation originating in Japan can benefit patients around the world.

Furthermore, we will uphold and carry forward the Association’s unique culture of

fostering frank dialogue between top executives. By encouraging direct participation from on-the-ground decision-makers, we aim to establish practical, reality-based policies and environments.

I will personally draw on my experience and network in the medical and biotech fields to learn alongside member companies, continue taking on new challenges, and contribute to the Association's further growth and fulfillment of its social responsibilities.

For a better future in healthcare.

And toward a society where every patient has reliable access to the care they need.

At SanBio, we will continue to strengthen efforts to realize our vision of becoming a global leader in regenerative medicine by contributing to the advancement of Japan's regenerative medicine industry.

For more information, contact:

SanBio Co., Ltd.

Management Administration

Email: info@sanbio.com